Enhanced S100A14 expression correlated positively with clinicopathological parameters in both in vitro and in vivo ovarian cancer systems, lending support for the use of S100A14 to determine clinicopathological stage and/or prognosis in ovarian cancer. This evidence concerns the gene S100A14 and ovarian cancer.